Novel kinase-activating genetic events in non-small cell lung carcinomas

Elena V. Preobrazhenskaya , Rimma S. Mulkidjan , Fyodor A. Zagrebin , Alexandr A. Romanko , Evgeniya S. Saitova , Polina R. Korzun , Jeyla O. Binnatova , Vladislav I. Tiurin , Ilya V. Bizin , Evgeny N. Imyanitov

Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) : 1002330

PDF (3265KB)
Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) :1002330 DOI: 10.37349/etat.2025.1002330
Original Article
research-article
Novel kinase-activating genetic events in non-small cell lung carcinomas
Author information +
History +
PDF (3265KB)

Abstract

Aim: This study aimed at the identification of new druggable alterations in non-small cell lung carcinomas (NSCLCs).

Methods: RNA next generation sequencing (NGS) analysis for 650 protein kinase genes was performed for 89 NSCLCs obtained from young-onset and/or female non-smokers, who were negative for activating events involving EGFR, ALK, ROS1, RET, MET, NTRK1/2/3, BRAF, HER2, KRAS, or NRAS genes.

Results: RNA sequencing identified 32 in-frame rearrangements, including 9 instances of fully preserved and 8 tumors with partially preserved tyrosine kinase domains. These 17 translocations were further analyzed in 1,059 mutation-negative NSCLCs, which resulted in the identification of two additional tumors with ADK:: KAT6B rearrangement and one carcinoma carrying RPS6KB1:: VMP1 fusion. The recently reported CLIP1:: LTK gene fusion was tested in 2,754 NSCLCs, which were negative for all known actionable mutations, however, no new instances of this translocation have been observed. We further analyzed RNA sequencing results of 89 NSCLCs for mutations affecting the kinase domain of the involved gene. There were 53 substitutions with a combined annotation dependent depletion (CADD) score above 25; all these lesions turned out to be unique, as the analysis of 551 additional NSCLCs revealed no recurrent alterations. ROS1, LTK, and FGFR4 high-level overexpression was observed in 1 out of 89 tumors each.

Conclusions: This study demonstrates the scarcity of yet unknown kinase-activating alterations in NSCLCs.

Keywords

Lung cancer / kinases / fusion / mutation / expression / RNA / next generation sequencing (NGS)

Cite this article

Download citation ▾
Elena V. Preobrazhenskaya, Rimma S. Mulkidjan, Fyodor A. Zagrebin, Alexandr A. Romanko, Evgeniya S. Saitova, Polina R. Korzun, Jeyla O. Binnatova, Vladislav I. Tiurin, Ilya V. Bizin, Evgeny N. Imyanitov. Novel kinase-activating genetic events in non-small cell lung carcinomas. Exploration of Targeted Anti-tumor Therapy, 2025, 6 (1) : 1002330 DOI:10.37349/etat.2025.1002330

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Yoshikawa S, Kukimoto-Niino M, Parker L, Handa N, Terada T, Fujimoto T, et al. Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor. Oncogene. 2013; 32: 27-38.

[2]

Uribe ML, Marrocco I, Yarden Y. EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance. Cancers (Basel). 2021; 13: 2748.

[3]

Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417: 949-54.

[4]

Harada G, Yang SR, Cocco E, Drilon A. Rare molecular subtypes of lung cancer. Nat Rev Clin Oncol. 2023; 20: 229-49.

[5]

Shreenivas A, Janku F, Gouda MA, Chen HZ, George B, Kato S, et al. ALK fusions in the pan-cancer setting: another tumor-agnostic target? NPJ Precis Oncol. 2023; 7: 101.

[6]

Drilon A, Jenkins C, Iyer S, Schoenfeld A, Keddy C, Davare MA. ROS1-dependent cancers-biology, diagnostics and therapeutics. Nat Rev Clin Oncol. 2021; 18: 35-55.

[7]

Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018; 15: 731-47.

[8]

Pruis MA, Geurts-Giele WRR, von der TJH, Meijssen IC, Dinjens WNM, Aerts JGJV, et al. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer. Lung Cancer. 2020; 140: 46-54.

[9]

Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, et al. ; GEOMETRY mono-1 Investigators. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N Engl J Med. 2020; 383: 944-57.

[10]

Spagnolo CC, Ciappina G, Giovannetti E, Squeri A, Granata B, Lazzari C, et al. Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story? Int J Mol Sci. 2023; 24: 10119.

[11]

Nützinger J, Bum Lee J, Li Low J, Ling Chia P, Talisa Wijaya S, Chul Cho B, et al. Management of HER2 alterations in non-small cell lung cancer-The past, present, and future. Lung Cancer. 2023; 186: 107385.

[12]

Imyanitov EN, Preobrazhenskaya EV, Orlov SV. Current status of molecular diagnostics for lung cancer. Explor Target Antitumor Ther. 2024; 5: 742-65.

[13]

Haas BJ, Dobin A, Li B, Stransky N, Pochet N, Regev A. Accuracy assessment of fusion transcript detection via read-mapping and de novo fusion transcript assembly-based methods. Genome Biol. 2019; 20: 213.

[14]

Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013; 31: 213-9.

[15]

Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 2011; 12: 323.

[16]

Izumi H, Matsumoto S, Liu J, Tanaka K, Mori S, Hayashi K, et al. The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer. Nature. 2021; 600: 319-23.

[17]

Shaw AT, Riely GJ, Bang YJ, Kim DW, Camidge DR, Solomon BJ, et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol. 2019; 30: 1121-6.

[18]

Drilon A, Chiu CH, Fan Y, Cho BC, Lu S, Ahn MJ, et al. Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC. JTO Clin Res Rep. 2022; 3: 100332.

[19]

Song Z, Lv D, Chen SQ, Huang J, Li Y, Ying S, et al. Pyrotinib in Patients with HER2-Amplified Advanced Non-Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial. Clin Cancer Res. 2022; 28: 461-7.

[20]

Peters S, Stahel R, Bubendorf L, Bonomi P, Villegas A, Kowalski DM, et al. Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers. Clin Cancer Res. 2019; 25: 64-72.

[21]

Cobleigh MA, Abukheir AM. Binimetinib activity in PIK3R1-mutant patient-derived xenografts (PDX) implanted into immunodeficient mice. J Clin Oncol. 2021; 39: e13062.

[22]

Sootome H, Fujita H, Ito K, Ochiiwa H, Fujioka Y, Ito K, et al. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors. Cancer Res. 2020; 80: 4986-97.

[23]

Siefker-Radtke AO, Necchi A, Park SH, García-Donas J, Huddart RA, Burgess EF, et al. ; BLC2001 Study Group. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study. Lancet Oncol. 2022; 23: 248-58.

[24]

Earp MA, Raghavan R, Li Q, Dai J, Winham SJ, Cunningham JM, et al. Characterization of fusion genes in common and rare epithelial ovarian cancer histologic subtypes. Oncotarget. 2017; 8: 46891-9.

[25]

Blum AE, Venkitachalam S, Guo Y, Kieber-Emmons AM, Ravi L, Chandar AK, et al. RNA Sequencing Identifies Transcriptionally Viable Gene Fusions in Esophageal Adenocarcinomas. Cancer Res. 2016; 76: 5628-33.

[26]

Stransky N, Cerami E, Schalm S, Kim JL, Lengauer C. The landscape of kinase fusions in cancer. Nat Commun. 2014; 5: 4846.

[27]

Zhu YC, Wang WX, Li XL, Xu CW, Chen G, Zhuang W, et al. Identification of a Novel Icotinib-Sensitive EGFR-SEPTIN14 Fusion Variant in Lung Adenocarcinoma by Next-Generation Sequencing. J Thorac Oncol. 2019; 14: e181-3.

[28]

Wang W, Lv W, Wang H, Xu Y, Yan J, Shen H, et al. A novel acquired EGFR-SEPT14 fusion confers differential drug resistance to EGFR inhibitors in lung adenocarcinoma. Genes Dis. 2023; 10: 2241-4.

[29]

Sweeney CJ, Hainsworth JD, Bose R, Burris HA, Kurzrock R, Swanton C, et al. MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid Tumors. J Clin Oncol. 2024; 42: 258-65.

[30]

Aleksakhina SN, Ivantsov AO, Imyanitov EN. Agnostic Administration of Targeted Anticancer Drugs: Looking for a Balance between Hype and Caution. Int J Mol Sci. 2024; 25: 4094.

[31]

Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008; 455: 1069-75.

PDF (3265KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉